Dual targeting of acute myeloid leukemia progenitors by catalytic mTOR inhibition and blockade of the p110a subunit of PI3 kinase

Marco Colamonici, Gavin Blyth, Diana Saleiro, Amy Szilard, Meghan Bliss-Moreau, Francis J. Giles, Jessica K. Altman, Elspeth M. Beauchamp, Leonidas C. Platanias*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

The mammalian target of rapamycin (mTOR) and phosphoinositide-3-kinase (PI3K) pathways are often aberrantly activated in acute myeloid leukemia (AML) and play critical roles in proliferation and survival of leukemia cells. We provide evidence that simultaneous targeting of mTOR complexes with the catalytic mTOR inhibitor OSI-027 and of the p110a subunit of PI3K with the specific inhibitor BYL-719 results in efficient suppression of effector pathways and enhanced induction of apoptosis of leukemia cells. Importantly, such a combined targeting approach results in enhanced suppression of primitive leukemic progenitors from patients with AML. Taken together, these findings raise the possibility of combination treatments of mTOR and p110a inhibitors as a unique approach to enhance responses in refractory AML.

Original languageEnglish (US)
Pages (from-to)8062-8070
Number of pages9
JournalOncotarget
Volume6
Issue number10
DOIs
StatePublished - 2015

Keywords

  • AML
  • MTOR signaling
  • PI3 kinase

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Dual targeting of acute myeloid leukemia progenitors by catalytic mTOR inhibition and blockade of the p110a subunit of PI3 kinase'. Together they form a unique fingerprint.

Cite this